PD-1 Inhibitor (sintilimab) and Fruquintinib Plus SOX As Conversion Therapy for Initially Unresectable Gastric/gastroesophageal Junction Adenocarcinoma (GC/GEJC): Updated Results from a Single-Arm, Phase 2 Clinical Trial.
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined